PPIDT00331

Drug Information
NameDupilumab
SequenceEVQLVESGGGLEQPGGSLRLSCAGSGFTFRDYAMTWVRQAPGKGLEWVSSISGSGGNTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDRLSITIRPRYYGLDVWGQGTTVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLG
DrugBank_IDDB12159
Typebiotech
IndicationIn the US, dupilumab is indicated for the treatment of patients aged six months and older with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.[L42005] In Europe and Canada, the drug for this indication is approved for patients aged six years and older.[L7192,L41439] In Europe, patients six to 11 years of age should have severe atopic dermatitis and be candidates for systemic therapy.[L7192] Dupilumab can be used with or without topical corticosteroids for this condition.[L7186,L41439] Dupilumab is indicated as an add-on maintenance treatment of patients aged six years and older with moderate-to-severe asthma characterized by an eosinophilic phenotype or with oral corticosteroid dependent asthma. However, the drug is not indicated for relief of acute bronchospasm or status asthmaticus.[L7186,L7192,L41439] Dupilumab is indicated as an add-on maintenance treatment in adult patients with inadequately controlled chronic rhinosinusitis with nasal polyposis.[L7186] In Canada and Europe, it is used with intranasal corticosteroids.[L7192,L41439] In the US and Europe, dupilumab is also indicated for the treatment of adults and children aged 12 years and older weighing at least 40 kg with eosinophilic esophagitis (EoE), and adults with prurigo nodularis.[L7192,L41900,L43297]
Dosage Forms
Form Route Strength
Injection Subcutaneous
Injection, solution Parenteral; Subcutaneous
100 mg
Injection, solution Parenteral; Subcutaneous
200 MG
Injection, solution Parenteral; Subcutaneous
300 MG
Injection, solution Subcutaneous
100 mg/0.67mL
Injection, solution Subcutaneous
150 mg/ml
Injection, solution Subcutaneous
175 mg/ml
Injection, solution Subcutaneous
200 mg/1.14mL
Injection, solution Subcutaneous
300 mg/2mL
Solution Subcutaneous
100 mg / 0.67 mL
Solution Subcutaneous
200 mg / 1.14 mL
Solution Subcutaneous
300 mg / 2 mL
Solution Subcutaneous
300.00 mg
Injection, solution —
175 mg/ml
Injection, solution —
200 mg/1.14ml
Solution Subcutaneous
200 mg
Injection, solution Subcutaneous
Injection, solution —
300 mg/2ml
Solution Subcutaneous
20000000 mg
Solution Subcutaneous
30000000 mg
Target Information
Role Uniprot_ID Gene_Name Entity_Name Organism Actions Internal link
target P24394 IL4R Interleukin-4 receptor subunit alpha Homo sapiens inhibitor|antibody Link
target P35225 IL13 Interleukin-13 Homo sapiens inhibitor|antibody Link
target P05112 IL4 Interleukin-4 Homo sapiens inhibitor|antibody Link